Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2000-11-15
2009-02-17
Maier, Leigh C (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S123130, C424S450000, C424S812000
Reexamination Certificate
active
07491707
ABSTRACT:
New synthetic Lipid-A analogs based on monosaccharide (1) and disaccharide (2) derivatives were designed and prepared in the present invention. Both structures (1) and (2) incorporate novel lipid structures (3) and (4) that are not found in nature. Also, novel disaccharide Lipid-A structures (2) that incorporate novel contingents of uniform lipids and where R1, R4and R5are the same substitution group of structure (III) were synthesized. Liposome formulations containing totally synthetic components such as synthetic Lipid-A and synthetic lipopeptide derived from tumor-associated MUC1 mucin are described along with their therapeutic utility. Comparative test results of immunostimulating properties and toxicity of Lipid-A analogs (1) and (2) are included.
REFERENCES:
patent: 4912094 (1990-03-01), Myers et al.
patent: 5134230 (1992-07-01), Kusama et al.
patent: 5554372 (1996-09-01), Hunter
patent: 5648343 (1997-07-01), Carlson
patent: 2005/0048076 (2005-03-01), Apicella et al.
patent: 0330715 (1989-09-01), None
patent: 0536969 (1993-03-01), None
patent: WO 95/14026 (1995-05-01), None
Wang, Y. et al “Acid and base hydrolysis of Lipid A . . .” J. Mass Sprectrom. (1996) vol. 31, pp. 138-149.
Karunaratne, D. et al “Characterization of Lipid A . . .” Arch. Biochem. Biophys. (1992) vol. 299, No. 2, pp. 368-376.
Grabarek, J. et al “Modulation of human platelet . . .” J. Clin. Invest. (1988) vol. 82, pp. 964-971.
Schromm, A. et al “The charge of endotoxin molecules influences their conformation . . .” J. Immunol. (1998) vol. 161, pp. 5464-5471.
Rietschel, E. et al “Bacterial endotoxin: molecular relationships . . .” FASEB J. (1994) vol. 8, pp. 217-225.
Imoto, M. et al “Chemical synthesis of a biosynthetic precursor of lipid A . . .” Bull. Chem. Soc. Jpn. (1987) vol. 60, pp. 2197-2204.
Samuel, J. et al “immunogenicity and antitumor activity . . .” Int. J. Cancer (1998) vol. 75, pp. 295-302.
Alving, Carl,Lipopolysaccharide, Lipid A, and Liposomes Containing Lipid A as Immunologic Adjuvants, Immunobiol., vol. 187, pp. 430-446, 1993.
Charon, et al.,Chemical Synthesis and Immunological Activities of Glycolipids Structurally Related to Lipid A, Biochemistry, vol. 24, pp. 2736-2742, 1985.
Christ et al.,E5531, a Pure Endotoxin Antagonist of High Potency, Science, vol. 268, pp. 80-83, Apr. 7, 1995.
Fink, et al.,Adoptive immunotherapy of Gram-negative sepsis: Use of monoclonal antibodies to lipopolysaccharide, Critical Care Medicine, vol. 21, No. 2, pp. S32-S39, 1993.
Fujishima, et al.,New synthetic immunomodulators combining a 4-O-phosphono-D-glucosamine derivative related to bacteria lipid A with 1-deoxy-N-acetylmuramoyl dipeptide analogs, Carbohydrate Research, vol. 167, pp. 317-324, 1987.
Goldman, et al.,Analysis of Lipopolysaccharide Biosynthesis in Salmonella typhimurium and Escherichia coli by Using Agents Which Specifically Block Incorporation of 3-Deoxy-D-manno-Octulosonate, Journal of Bacteriology, vol. 170, No. 5, pp. 2185-2191, May 1988.
Goldman, et al.,Inhibition of lipopolysaccharide synthesis in Agrobacterium tumefaciens and Aeromonas salmonicida, Journal of General Microbiology, vol. 138, pp. 15271533, 1992.
Kiso, et al.,Synthesis of 2-Deoxy-4-O-Phosphono-3-O-Tetradecanoyl-2-[(3/R)—and(3s)-3-Tetradecanoyloxytetradecanamidol]-D-Glucose: A Diastereoisomeric Pair of 4-O-Phosphono-D-Glucosamine Derivatives(GLA-27)Related to Bacterial Lipid A, Carbohydrate Research, vol. 148, pp. 221-234, 1986.
Kotani, et al.,Immunobiological Activities of Synthetic Lipid A Analogswith Low Endotoxicity, Infection and Immunity, vol. 54, No. 3, pp. 673-682, Dec. 1986.
Kotani, et al.,Low Endotoxic Activities of Synthetic Salmonella-Type Lipid A with an Additional Acyloxyacyl Group on the 2-Amino Group of β)1-6)Glucosamine Disaccharide 1,4′-Bisophosphate, Infection and Immunity, vol. 52, No. 3, pp. 872-884, Jun. 1986.
Onishi, et al.,Antibacterial Agents That Inhibit Lipid A Biosynthesis, Science, vol. 274, pp. 980-982, Nov. 8, 1996.
Sato, et al.,Synthetic Lipid A Analog with Low Endotoxicity, Dt-5461, Prevents Lethal Endotoxemia, Infection and Immunity, vol. 63, No. 8, pp. 2859-2866, Aug. 1995.
Takahashi, et al.,Requirement of a Properly Acylated β(1-6)-D-Glucosamine Disaccharide Bisphosphate Structure for Efficient Manifestation of Full Endotoxic and Associated Bioactivities of Lipid A, Infection and Immunity, vol. 65, No. 1, pp. 57-68, Jan. 1987.
Takayama, et al.,Separation and Characterization of Toxic and Nontoxic Forms of Lipid A, Reviews of Infectious Diseases, vol. 6, No. 4, pp. 439-443, Jul.-Aug. 1984.
Takayama, et al.,Use of Endotoxin in Cancer Immunotherapy and Characterization of Its Nontoxic but Active Lipid A Components, pp. 219-233, American Chemical Society, 1983.
Ulrich, et al.,Monophosphoryl Lipid A as an Adjuvant: Past Experiences and New Directions, Pharm. Biotechnol., vol. 6, pp. 495-525, 1995.
Vaara, Martti,Lipid A: Target for Antibacterial Drugs, Science, vol. 274, pp. 939-940, Nov. 8, 1996.
Von Eschen, Kenneth B.,Monophosphoryl Lipid A and Immunotherapy , vol. II: Immunopharmacology and pathophysiology, D.C. Morrison and J. L. Ryan (eds.), CRC Press, Boca Raton, Ann Arbor, London, Tokyo, pp. 411-428, 1992.
Werner, et al.,Immunostimulating agents: what next? A review of their present and potential medical applications, Eur. J. Biochem., vol. 242, pp. 1-19, 1996.
Bach Mimi
Jiang Zi-Hua
Koganty Rao
Longenecker Michael
Yalamati Damayanthi
Biomira, Inc.
Cooper Iver P.
Maier Leigh C
LandOfFree
Synthetic lipid-a-analogs and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthetic lipid-a-analogs and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthetic lipid-a-analogs and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4097334